Kalaris Therapeutics, Inc.
KLRS•NASDAQ•Healthcare•Biotechnology

About Kalaris Therapeutics

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOAndrew Oxtoby
Founded2019
Employees14
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitekalaristx.com
Address
628 Middlefield Road Palo Alto, California 94301 United States

Corporate Identifiers

CIK0001754068
CUSIP482929106
ISINUS4829291065
EIN83-1971007
SIC2836

Leadership Team & Key Executives

Andrew Oxtoby
President, Chief Executive Officer and Director
Dr. Srinivas Akkaraju M.D., Ph.D.
Director and Co-Founder
Dr. Michael Philip Dybbs Ph.D.
Director and Co-Founder
Dr. Napoleone Ferrara M.D.
Independent Director and Co-Founder
Matthew Gall M.B.A.
Chief Financial Officer and Treasurer
Brett R. Hagen
Chief Accounting Officer
Dr. Matthew Feinsod M.D.
Chief Medical Officer
Kristine Curtiss
Senior Vice President of Clinical